Evidence map›Paper›PMID 32427884›Full record

ArticleScientific reports2020

Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer.

Yu-Fan Chiu, Chia-Chang Wu, Ming-Han Kuo, Chia-Cheng Miao, Ming-Yi Zheng, Pei-Yu Chen, Sheng-Chieh Lin, Junn-Liang Chang, Yuan-Hung Wang, Yu-Ting Chou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.American journal of clinical and experimental urology · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yu-Fan Chiu *Institute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
Chia-Chang Wu *Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Ming-Han KuoInstitute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
Chia-Cheng MiaoInstitute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
Ming-Yi ZhengInstitute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
Pei-Yu ChenInstitute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
Sheng-Chieh LinInstitute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
Junn-Liang ChangDepartment of Pathology and Laboratory Medicine, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan.
Yuan-Hung WangDepartment of Medical Research, Shuang Ho Hospital, New Taipei City, Taiwan. d508091002@tmu.edu.tw.
Yu-Ting ChouInstitute of Biotechnology, College of Life Science, National Tsing Hua University, Hsinchu, Taiwan. ytchou@life.nthu.edu.tw.ORCID http://orcid.org/0000-0001-9274-8603
National Tsing Hua University · TWTaipei Medical University-Shuang Ho Hospital · TWChina Medical University · TWMing Chuan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Signaling elicited by the stem cell factors SOX2, OCT4, KLF4, and MYC not only mediates reprogramming of differentiated cells to pluripotency but has also been correlated with tumor malignancy. In this study, we found SOX2 expression signifies poor recurrence-free survival and correlates with advanced pathological grade in bladder cancer. SOX2 silencing attenuated bladder cancer cell growth, while its expression promoted cancer cell survival and proliferation. Under low-serum stress, SOX2 expression promoted AKT phosphorylation and bladder cancer cells' spheroid-forming capability. Furthermore, pharmacological inhibition of AKT phosphorylation, using MK2206, inhibited the SOX2-mediated spheroid formation of bladder cancer cells. Gene expression profiling showed that SOX2 expression, in turn, induced IGF2 expression, while SOX2 silencing inhibited IGF2 expression. Moreover, knocking down IGF2 and IGF1R diminished bladder cancer cell growth. Lastly, pharmacological inhibition of IGF1R, using linsitinib, also inhibited the SOX2-mediated spheroid formation of bladder cancer cells under low-serum stress. Our findings indicate the SOX2-IGF2 signaling affects the aggressiveness of bladder cancer cell growth. This signaling could be a promising biomarker and therapeutic target for bladder cancer intervention.

Indexed as

HumansInsulin-Like Growth Factor IIKruppel-Like Factor 4PhosphorylationProto-Oncogene Proteins c-aktReceptor, IGF Type 1Signal TransductionSOXB1 Transcription FactorsUrinary Bladder NeoplasmsIGF1R protein, humanInsulin-Like Growth Factor IIKLF4 protein, humanKruppel-Like Factor 4Proto-Oncogene Proteins c-aktReceptor, IGF Type 1SOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID32427884
PMCPMC7237425
OpenAlexW3026350409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.